Clinical Trial Detail

NCT ID NCT02892201
Title Pembrolizumab in HNSCC With Residual Disease After Radiation
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Yale University

hypopharynx cancer

oral squamous cell carcinoma

head and neck squamous cell carcinoma

oropharynx cancer

nasopharynx carcinoma

laryngeal squamous cell carcinoma



Age Groups: adult senior

No variant requirements are available.